Aclaris Therapeutics IPO

10/7/2015

IPO

$55,000,000

We currently estimate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $22.0 million to complete our three planned Phase 3 clinical trials and seek regulatory approval of A-101 for the treatment of SK; approximately $13.0 million to fund continued research and development of A-101 for the treatment of common warts, including the completion of our planned Phase 2 clinical trials for this indication; and the remainder to fund other research and development activities, including the development of A-102 for the treatment of SK and common warts and the development of A-201 and A-301 for the treatment of AA, as well as for working capital and other general corporate purposes, including to pursue our strategy to in-license or acquire additional drug candidates, although we have no agreements or commitments for any specific acquisitions or in-licenses as of the date of this prospectus.

Publicly-held

Biopharmaceutical

640 Lee Rd. 200
Wayne, PA 19087
USA

Aclaris Therapeutics, Inc. (ACRS) is a specialty pharmaceutical company focused on identifying, developing and commercializing novel dermatologic treatments.